Overview
BIOA market data
Price History
BIOA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -871.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.33 – $25.96 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $525.5M · P/B 1.74 · P/S 50.94.
Company News
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price TargetBenzinga · Aug 6, 2026, 9:23 AM
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M EstimateBenzinga · Aug 5, 2026, 9:19 PM
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobenewswire Inc · Aug 5, 2026, 9:15 PM
8-K filing — BioAge Labs, Inc. (BIOA)SEC EDGAR · Aug 5, 2026, 8:55 PM
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35Benzinga · Jul 31, 2026, 8:08 PM
Why Is BioAge Labs Stock Sinking Friday?Benzinga · Jul 31, 2026, 5:24 PM
BioAge Labs shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.Benzinga · Jul 31, 2026, 4:20 PM
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat EarningsBenzinga · Jul 31, 2026, 1:44 PM
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskGlobenewswire Inc · Jun 16, 2026, 12:15 PM
BioAge Labs Doses First Participant Dosed In QUELL-CVBenzinga · Jun 16, 2026, 12:05 PM